- Glycopyrronium – a newly funded treatment for chronic obstructive pulmonary disorder
- Indacaterol - a newly funded treatment for chronic obstructive pulmonary disorder
- Omalizumab – a newly funded treatment for severe allergic asthma
- Tobramycin – an newly funded inhalation for cystic fibrosis
Four new treatments for respiratory conditions became funded from 1 November 2014. These included two medicines, glycopyrronium and indacaterol for chronic obstructive pulmonary disorder (COPD), omalizumab for severe allergic asthma, and an inhalation form of the antibiotic tobramycin for cystic fibrosis.
Omalizumab is a new generation treatment for asthma. It’s an injection that’s shown to be particularly effective in allergic asthma, and would likely help patients with the most severe forms better control their symptoms and avoid regular hospital treatment. About 180 patients over five years are likely to use funded omalizumab.
Previously, only one medicine – tiotropium – was funded specifically for COPD. Having two further funded medicines specifically registered for the treatment of COPD symptoms provides greater choice for clinicians and patients to tailor their treatment.
PHARMAC estimates about 10,000 patients could benefit from these new COPD medicines over five years.
The inhalation form of tobramycin contains no preservatives and is specifically formulated for inhalation, which makes it more suitable for patients.
All of the medicines were funded as part of the multi-product agreement with pharmaceutical company Novartis.
Last updated: 4 July 2017